Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech (NASDAQ: ALVO) is a biotechnology company dedicated exclusively to biosimilars, and its news flow reflects the progress of a global biosimilar platform. Company updates frequently cover regulatory milestones, such as marketing authorizations in the European Economic Area, the United Kingdom and Japan for products referencing Prolia and Xgeva (denosumab), Simponi (golimumab) and Eylea (aflibercept). Press releases also highlight clinical and regulatory developments for new candidates, including submissions to agencies like the European Medicines Agency and the U.S. Food and Drug Administration.
Investors following ALVO news can expect regular announcements on product approvals, pipeline progress and legal or regulatory outcomes. Recent communications have described European Commission approval of AVT03, a biosimilar to Prolia and Xgeva, positive opinions from EMA committees for AVT03 and AVT05, and a settlement and license agreement enabling a future U.S. launch of AVT06, a proposed biosimilar to Eylea, subject to FDA approval. Other items include court decisions related to manufacturing activities for AVT06 and updates on applications for additional candidates such as AVT23.
Alvotech’s news flow also includes capital markets and financing transactions, such as senior unsecured convertible bond offerings and a senior term loan facility, which the company states are intended to support its research and development pipeline, manufacturing capacity and global product launches. Earnings-related press releases and business updates provide guidance ranges for revenues and adjusted EBITDA, along with commentary on order books, launch timing and investment programs.
Corporate governance and leadership changes are another recurring theme. For example, Alvotech has announced a planned CEO succession in which the founder will remain as Executive Chairman while a new Chief Executive Officer takes over day-to-day leadership. For users tracking ALVO, this news page offers a centralized view of regulatory, financial and strategic developments affecting the company’s biosimilar portfolio and global partnerships.
Alvotech (NASDAQ: ALVO) has received a positive recommendation from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for AVT03, its proposed biosimilar to Prolia® and Xgeva® (denosumab).
Upon approval, the biosimilar will be marketed by STADA Arzneimittel AG and Dr. Reddy's Laboratories SA with semi-exclusive commercial rights in Europe, including Switzerland and the UK. The biosimilar will be available in two formulations: a 60 mg/mL pre-filled syringe and a 70 mg/mL vial, targeting conditions including osteoporosis in postmenopausal women, bone loss in cancer patients, and giant cell tumor of bone.
Alvotech (NASDAQ: ALVO) and Advanz Pharma have announced that the European Medicines Agency's CHMP has recommended marketing approval for Gobivaz®, a proposed biosimilar to Simponi® (golimumab). The biosimilar is intended for treating several chronic inflammatory diseases.
The recommendation covers 50 mg/0.5mL and 100mg/mL dosages in pre-filled syringe and autoinjector forms. The treatment is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis in adults and juvenile idiopathic arthritis across the EU, Norway, Iceland, and Lichtenstein.
The recommendation follows successful clinical trials, including positive top-line results from a confirmatory study in April 2024 and a pharmacokinetic study in November 2023.
Alvotech (NASDAQ: ALVO) has secured marketing approval from the Japanese Ministry of Health, Labor and Welfare for three new biosimilars through its partner Fuji Pharma. The approved products include: AVT03 (biosimilar to Ranmark®/denosumab), AVT05 (first-to-market biosimilar to Simponi®/golimumab), and AVT06 (biosimilar to Eylea®/aflibercept).
These approvals follow Alvotech's successful launch of its Stelara® biosimilar in Japan last year. The company's partnership with Fuji Pharma, established in 2018, includes rights to two additional biosimilar candidates under development, bringing their total collaboration to six products.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York from September 8-10, 2025.
The company will conduct investor meetings on September 9, followed by a fireside chat featuring Dr. Balaji Prasad, Chief Strategy Officer, on September 10 at 10:45 am EDT. The fireside chat will be publicly accessible via webcast on Alvotech's investor relations website, with a 90-day replay period available after the event.
Alvotech (NASDAQ: ALVO) and Advanz Pharma have entered into a supply and commercialization agreement for AVT10, Alvotech's biosimilar candidate to Cimzia® (certolizumab pegol). The partnership targets the European market, with AVT10 being the only Cimzia® biosimilar under global development.
Cimzia®, a TNF-alpha inhibitor for inflammatory diseases, generated worldwide sales of US$2.3 billion in 2024. The companies plan to launch their first biosimilars in Europe in Q4 2025. This agreement adds to their existing partnership covering biosimilar candidates for more than ten reference biologics.
Alvotech (NASDAQ: ALVO) and Advanz Pharma have received European Commission approval for Mynzepli®, a biosimilar to Eylea® (aflibercept), for treating various retinal diseases. The approval covers all European Economic Area countries and follows positive clinical trial results demonstrating therapeutic equivalence to Eylea®.
The biosimilar is approved for treating multiple eye conditions including wet age-related macular degeneration (AMD), macular edema, diabetic macular edema (DME), and myopic choroidal neovascularization. Notably, Eylea® generated global sales of approximately $9 billion in 2024, with one-third from Europe.
Mynzepli® will be available as a 40 mg/mL solution for injection in both pre-filled syringe and vial formats. The approval is currently under review in other major markets, including the United States and Japan.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has appointed Patrik Ling as VP of Investor Relations Scandinavia, based in Stockholm. Ling brings over 25 years of life-science industry experience, most recently serving as Senior Equity Analyst at DNB Carnegie where he covered life science companies including Alvotech.
The appointment aligns with Alvotech's strategy to expand its Scandinavian shareholder base and strengthen its position as a leading Nordic life science company. Ling's background spans both pharmaceutical and financial sectors, including roles in marketing, sales, portfolio management, and equity analysis.
Alvotech (NASDAQ: ALVO), a global biotech company, has secured improved terms on its senior secured term loan facility. The company's lenders, including GoldenTree Asset Management, have agreed to reduce interest rates, resulting in estimated savings of $8.2 million in interest payments over the first 12 months.
The facility, which matures in July 2029, will be consolidated into a single tranche with an interest rate of SOFR plus 6.0% per annum, down from previous rates of SOFR plus 6.5% and 10.5%. The total facility balance stands at $1,081 million, with the company maintaining a cash balance of $152 million as of June 25, 2025.
Alvotech (NASDAQ: ALVO) reported strong financial results for H1 2025, highlighted by a 210% year-over-year increase in product revenue to $204.7 million. The company achieved its best quarter ever in operating cash flows and expanded its commercial partnerships.
Key developments include the acquisition of Xbrane's R&D facilities in Sweden and Ivers-Lee Group in Switzerland, strengthening its end-to-end biosimilars platform. The company successfully listed on Nasdaq Stockholm, completed two SDR offerings raising approximately SEK 789 million, and amended its term loan to reduce interest expenses by $8.2 million annually.
Financial highlights include $151.5 million in cash, operating profit of $28.6 million, and net profit of $141.7 million ($0.50 per share). The company also expanded partnerships with Advanz Pharma and Dr. Reddy's Laboratories for multiple biosimilar candidates.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its first half 2025 financial results announcement. The company will release its financial results for the period ending June 30, 2025 after U.S. markets close on August 13, 2025.
A conference call and webcast to discuss the results and business highlights will be held on August 14, 2025, at 8:00 am EDT. The presentation will be accessible through Alvotech's investor portal, with a replay available for 90 days following the event.